⌕
Insmed · INSM · Nasdaq
Tenet 33 · Weak
Compare
$121.86−0.83%At closeTenet 33 · Weak
$121.86−1.02 (−0.83%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$119.48−2.38 (−1.95%)
After hours: Nov 17, 2026, 5:11 PM ET

Insmed (INSM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is INSM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 17, 2026 · 02:12 ET
Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead

Insmed NASDAQ: INSM expects its bronchiectasis drug BRINSUPRI to generate $1.35 billion to $1.4 billion in its first full year of launch, Chief Executive Officer Will Lewis said, as the company looks to reach more patien…

INSM −0.8% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 11:53 ET
Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

INSM −0.8% todayRead at source ↗
● Zacks Investment ResearchNov 10, 2026 · 10:16 ET
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.…

INSM −0.8% todayRead at source ↗
● Seeking AlphaNov 7, 2026 · 05:43 ETEARNINGS EXPECTED BY FEB 22
Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance

Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales growth for three years,…

INSM −0.8% todayRead at source ↗
● PRNewsWireNov 4, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Insmed to Present at November and December 2026 Investor Conferences

BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patient…

INSM −0.8% todayRead at source ↗
● Seeking AlphaOct 30, 2026 · 21:48 ETEARNINGS EXPECTED BY FEB 22
Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript

Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer Conference Call Partici…

INSM −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 11:31 ETEARNINGS EXPECTED BY FEB 22
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance

Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.…

INSM −0.8% todayRead at source ↗
● MarketBeatOct 29, 2026 · 14:15 ETEARNINGS EXPECTED BY FEB 22
What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.…

INSM −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 10:31 ETEARNINGS EXPECTED BY FEB 22
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street est…

INSM −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 09:36 ETEARNINGS EXPECTED BY FEB 22
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates

Insmed (INSM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $1.75 per share a year ago.…

INSM −0.8% todayRead at source ↗
● PRNewsWireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 22
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ®  (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026— —ARIKA…

INSM −0.8% todayRead at source ↗
● Defense WorldOct 28, 2026 · 04:05 ETEARNINGS EXPECTED BY FEB 22
Citizens Financial Group Inc. RI Makes New Investment in Insmed, Inc. $INSM

Citizens Financial Group Inc. RI acquired a new position in shares of Insmed, Inc. (NASDAQ: INSM) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institution…

INSM −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 22, 2026 · 11:02 ETEARNINGS EXPECTED BY FEB 22
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

INSM −0.8% todayRead at source ↗
● PRNewsWireOct 20, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Insmed Appoints Two New Directors to Its Board

—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J., Oct. 20, 2026 /PRNewsw…

INSM −0.8% todayRead at source ↗
● PRNewsWireOct 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026 /PRNewswire/ -- Insmed …

INSM −0.8% todayRead at source ↗
● PRNewsWireOct 15, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of the Broadest Active G…

INSM −0.8% todayRead at source ↗
● PRNewsWireOct 14, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With…

INSM −0.8% todayRead at source ↗
● Defense WorldOct 14, 2026 · 04:09 ETEARNINGS EXPECTED BY FEB 22
Perpetual Ltd Acquires 5,760 Shares of Insmed, Inc. $INSM

Perpetual Ltd raised its holdings in shares of Insmed, Inc. (NASDAQ: INSM) by 164.0% in a recent quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund …

INSM −0.8% todayRead at source ↗
● BenzingaOct 12, 2026 · 09:03 ET
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.…

INSM −0.8% todayRead at source ↗
● Zacks Investment ResearchOct 6, 2026 · 12:31 ETEARNINGS EXPECTED BY FEB 22
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.…

INSM −0.8% todayRead at source ↗
● BenzingaOct 5, 2026 · 11:59 ETEARNINGS EXPECTED BY FEB 22
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed

Insmed Inc. (NASDAQ:INSM) shares are trading lower by almost 7% on Monday as traders digest a CFO transition update alongside a slightly softer risk tone.…

INSM −0.8% todayRead at source ↗
● PRNewsWireOct 5, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 22
Insmed Announces CFO Transition

— Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership — — Company Reaffirms Full-Year 2026 Financial Guidance — — Company Announces Third-Quarter 2026 Financial Results Conf…

INSM −0.8% todayRead at source ↗
● Zacks Investment ResearchSep 22, 2026 · 13:25 ET
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.…

INSM −0.8% todayRead at source ↗
● PRNewsWireSep 21, 2026 · 07:00 ETEARNINGS EXPECTED BY FEB 22
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

—sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study— —Full Approval Could Bring ARIKAYCE to Patients Earlier in Their Disease Course and Would Fulfill Post-Marketing Requirement F…

INSM −0.8% todayRead at source ↗
● PRNewsWireSep 16, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Insmed Expands Community Impact During Fifth Annual Global Day of Good

Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout the U.S., Europe, and Japan BRIDGEWATER, N.J., Sept. 16, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq:…

INSM −0.8% todayRead at source ↗
● PRNewsWireSep 4, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patien…

INSM −0.8% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 22. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just INSM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.